Welcome to our dedicated page for Dariohealth news (Ticker: DRIO), a resource for investors and traders seeking the latest updates and insights on Dariohealth stock.
DarioHealth Corp. (NASDAQ: DRIO) is a digital health company focused on multi-chronic condition management through a user-centric digital therapeutics platform, and its news flow reflects developments across technology, clinical evidence, commercial traction and corporate strategy. News items frequently describe how Dario’s platform and suite of solutions deliver personalized, dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
Recent announcements have highlighted the launch of DarioIQ™, an artificial intelligence layer integrated into the Dario Health app. This AI capability, initially introduced for a cohort of hypertension members in a direct-to-consumer setting, is described as a clinically aligned, conversational layer that integrates behavioral insights, real-time biometric interpretation and personalized guidance while working alongside Dario’s human coaching framework. The company’s news coverage explains how DarioIQ™ is intended to enhance chronic condition management without replacing human-centered guidance.
DarioHealth’s news also emphasizes peer-reviewed clinical and economic evidence. Publications in JMIR Cardio and the Journal of Medical Internet Research (JMIR) have been featured in press releases, detailing studies of data-driven digital nudges for blood pressure management and analyses of healthcare utilization and medical costs among adults with type 2 diabetes using Dario’s platform compared to matched individuals receiving usual care. These articles are presented as supporting evidence for Dario’s ability to impact outcomes and healthcare burden.
Investors and observers following DRIO news will also see updates on employer and health plan adoption, including the signing of new employer clients and expansion of Dario’s commercial pipeline, as well as financing events such as private placements and strategic reviews initiated by the Board of Directors. Together, these news items provide context on how DarioHealth develops its technology, validates its approach through research and pursues growth with payers, employers and partners.
DarioHealth (NASDAQ: DRIO) reported Q4 2025 revenue of $5.2M and full-year 2025 revenue of $22.4M versus $27.0M in 2024, driven by a legacy client nonrenewal after the Twill acquisition.
Key metrics: GAAP gross margin 57%, pipeline $122M, contracted/late-stage ARR $12.9M, cash $26M, and full-year operating expenses down 31% to $49.3M.
DarioHealth (Nasdaq: DRIO) will report fourth quarter and full year 2025 results before the market opens on Thursday, March 19, 2026.
The company will host a conference call and webcast at 8:30 a.m. Eastern Time with CEO Erez Raphael, President Steven Nelson, and CFO Chen Franco-Yehuda. A replay will be available through Thursday, April 2, 2026.
DarioHealth (NASDAQ: DRIO) published a peer-reviewed ML study in Frontiers in Digital Health on March 10, 2026, analyzing real-world data from 22,414 adults with type 2 diabetes.
Researchers used generalized linear mixed-effects tree models and found sustained blood glucose improvements linked to higher digital engagement; 12 measurements per month emerged as an actionable threshold for glycemic improvement.
DarioHealth (NASDAQ: DRIO) positions its digital platform to boost real-world outcomes for patients using oral GLP-1 therapies by embedding precision behavioral support at scale. Key facts: 79% of members use Dario's weight management, and oral GLP-1s are projected to capture 25% of the GLP-1 market worth $95B by 2030 per Goldman Sachs. Dario highlights medication adherence tools, a grocery scanner and human coaches to reduce dose-timing drift, manage side effects and improve persistence for payers and employers.
DarioHealth (NASDAQ: DRIO) announced it has surpassed 100 peer-reviewed studies and conference abstracts as of Jan 21, 2026, reinforcing its evidence base for employers, health plans and members.
The research portfolio includes large study populations, longitudinal designs (some up to two years), independent third-party investigator-initiated studies, and directly observed outcomes such as actual claims reduction and measured HbA1c improvement. Dario says the body of work positions it among the most evidence-based digital health vendors and supports value-based purchasing and vendor consolidation decisions.
Dario Health (NASDAQ: DRIO) launched DarioIQ™, a new conversational AI layer in the Dario Health app, rolling out a direct-to-consumer first version on Dec 10, 2025 to an opt-in cohort of hypertension members.
DarioIQ™ integrates behavioral insights, real-time biometric interpretation, device connectivity and human coaching across three components — Advisor, Sentinel and Strategist — and builds on the company’s proprietary AI models and 13 billion real-world data points. The company plans staged expansion to employers and health plans and to other chronic pathways including diabetes and weight management, prioritizing safety and clinical validation.
DarioHealth (NASDAQ: DRIO) announced a private placement to sell 2,713,180 shares of common stock (or equivalents) at $6.45 per share for expected gross proceeds of approximately $17.5 million.
The closing is expected on or about September 23, 2025, subject to customary closing conditions. The company intends to use net proceeds for general corporate purposes and will file a registration statement with the SEC to register resale of the placed shares. The offering is being made in reliance on exemptions under Section 4(a)(2) of the Securities Act and/or Regulation D and applicable state securities laws.
DarioHealth (NASDAQ: DRIO) announced a peer-reviewed JMIR Cardio study (Dec 4, 2025) showing that data-driven digital nudges from its platform were associated with sustained blood pressure (BP) improvements in real-world users.
Key findings: users with high BP saw a larger monthly systolic BP reduction after three months (B = –2.09; P < .001) versus propensity-matched controls (B = –1.06; P = .007); users with higher lifestyle activity achieved greater reduction (B = –5.27; P < .001). 59% of Dario clients use its cardio-metabolic suite.
DarioHealth (NASDAQ: DRIO) announced 34 new employer clients in the past two weeks, bringing 79 clients signed year-to-date, surpassing its 2025 target of 40 new clients by 98%. The new agreements cover tens of thousands of lives and are expected to start contributing to revenue in Q1 2026. Nearly all new clients selected Dario for integrated cardiometabolic care. The company cites clinical outcomes including a 1.4% eHbA1c reduction, 38% blood pressure reduction by one stage, and 10% average BMI reduction. A recent JMIR real-world study with Sanofi and Symphony Health reported 23% lower hospitalization rates and 26% lower all-cause charges for Dario users versus matched usual-care individuals.
DarioHealth (NASDAQ: DRIO) announced publication of a peer-reviewed retrospective cohort study in Journal of Medical Internet Research showing estimated real-world savings and lower utilization for adults with type 2 diabetes using the Dario digital health platform versus matched usual-care individuals.
Key findings: 23.5% lower inpatient hospitalization rates, 26% lower all-cause healthcare resource utilization charges, and an estimated $5,077 gross medical cost savings per patient per year. The 12-month analysis covered 2,445 Dario users vs 7,334 matched controls and reported shorter lengths of stay, lower 30-day readmissions, and a dose-response link between engagement and fewer inpatient/ER events.